Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | CVP, TMTT, Surgical & IHFM | September 11, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date September 11, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,926 |
Reported balance
After 2026-09-11 transaction · row 1
1 source rowRow 1 · 2026-09-11 · Tax withholding · Disposed 398 · Balance 43,926 F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations incident to the vesting of securities in accordance with Rule 16b-3(e). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations incident to the vesting of securities in accordance with Rule 16b-3(e).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 07, 2020 Filed May 8, 2020 23:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 1,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007338 · doc4.xml · derivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,450 Underlying: Common Stock · 1,450 shares Expires 2027-05-06 F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 07, 2020 Filed May 8, 2020 23:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 10,600 | $0.00 Strike: $218.04 | $0.00 |
DisclosureSEC source: 0001225208-20-007338 · doc4.xml · derivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,600 Underlying: Common Stock · 10,600 shares Expires 2027-05-06 F2 · derivative.exercise_date: These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2020 Filed May 8, 2020 23:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,175 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007338 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,684 F1 · shares: These restricted stock units were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2019 Filed May 10, 2019 17:54 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 1,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000026 · primary_doc.xml · derivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,625 Underlying: Common Stock · 1,625 shares Expires 2026-05-07 F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · balance_after: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 08, 2019 Filed May 10, 2019 17:54 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 11,500 | $0.00 Strike: $177.77 | $0.00 |
DisclosureSEC source: 0001223203-19-000026 · primary_doc.xml · derivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2026-05-07 F2 · derivative.exercise_date: These options were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2019 Filed May 10, 2019 17:54 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000026 · primary_doc.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,509 F1 · shares: These restricted stock units were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. Read SEC document |
| May 17, 2018 Filed May 22, 2018 00:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 16,145 | $0.00 Strike: $135.83 | $0.00 |
DisclosureSEC source: 0001225208-18-009686 · doc4.xml · derivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, Surgical HVT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,145 Underlying: Common Stock · 16,145 shares Expires 2025-05-16 F2 · derivative.exercise_date: These options were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 17, 2018 Filed May 22, 2018 00:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 2,209 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009686 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, Surgical HVT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,209 F1 · shares: These restricted stock units were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.